CN1375289A - Ampelosis general flavone composition with liver protecting function - Google Patents
Ampelosis general flavone composition with liver protecting function Download PDFInfo
- Publication number
- CN1375289A CN1375289A CN 01109641 CN01109641A CN1375289A CN 1375289 A CN1375289 A CN 1375289A CN 01109641 CN01109641 CN 01109641 CN 01109641 A CN01109641 A CN 01109641A CN 1375289 A CN1375289 A CN 1375289A
- Authority
- CN
- China
- Prior art keywords
- composition
- flavonid
- flavonid composition
- ampelopsis
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention has opend a common flavone combination which can cure hepatitis, protect liver and has antiphlogistic and antibacterial actions as well as can enhance the immunological competence of immunological system to the public. It contains 10-70 wt% porcelain vine, 0.5-3 wt% myricitrin and 0.2-3 wt% gallic acid. Its preparing method and also its functions in preparing drinks, health care product and medicine of curing heapatitis, protecting liver, antibacterial action, antiphlogistic action and enhancing immunological competence of immunological system are opened to the public.
Description
The invention belongs to treatment hepatitis, hepatoprotective health care, anti-inflammation, blood fat reducing, analgesia, blood fat reducing is eliminated the phlegm in the natural medicine field analgesia of eliminating the phlegm and improving body immunity.
The present invention relates to a kind of flavonid composition and preparation method thereof, and in preparation treatment hepatitis, hepatoprotective health care, anti-inflammation, blood fat reducing, analgesia is eliminated the phlegm and is improved the purposes of the medicine and the health product of body immunity.
Vitaceae is usually used in medical herbs, and its stem, leaf, skin and root are all pharmaceutically acceptable.Have effects such as heat-clearing and toxic substances removing, dampness removing, be used for the treatment of furuncle abscess, trauma infection contamination, laryngopharynx swelling and pain, pulmonary tuberculosis, cough due to lung-heat, pyretic stranguria, edema, traumatic injury and nephritis etc.The bitter edible plant is also made with its stem and leaf in certain areas, is used to relieve summer heat, quench the thirst.
In recent years, China's researcher extracts its composition and separates, and has therefrom separated some chemical compounds, as dihydromyricetin etc.Also there are some scholars that its pharmacological action is studied.Its water decoction can obviously be alleviated drunk reaction, and the mild flesh of intestinal is had tangible excitation; Radix ampelopsis brevipedunculatae endothelium water decoction treatment herpes zoster is obtained better curative effect; Can also treat suppurative dermatosis, also obtain better curative effect.
The applicant is surprisingly found out that a kind of ampelopsin (10-70wt%) that contains, arbutin (0.5-3wt%), the flavonid composition of gallic acid (0.2-3wt%), and find that further this flavonid composition has treatment hepatitis, the hepatoprotective health care, anti-inflammation, blood fat reducing, analgesia is eliminated the phlegm and the effect of enhance immunity systemic immunity power.This flavonid composition can be directly as medicine or can make pharmaceutical composition with pharmaceutical acceptable carrier or mixed with excipients.This flavonid composition can obtain from vitaceae.Also can obtain by the chemical field conventional method.
An object of the present invention is to provide a kind of flavonid composition, wherein contain ampelopsin (10-70wt%), arbutin (0.5-3wt%), gallic acid (0.2-3wt%).
An object of the present invention is to provide a kind of method of from vitaceae, extracting above-mentioned flavonid composition.
Another object of the present invention provides the pharmaceutical composition that contains above-mentioned flavonid composition.
Another object of the present invention provides health product or the beverage that contains above-mentioned flavonid composition.
Another object of the present invention is above-mentioned flavonid composition in preparation treatment hepatitis and hepatoprotective effect and antiinflammatory, blood fat reducing, and analgesia is eliminated the phlegm or is improved purposes in the pharmaceutical composition of immunity.
The present composition is to obtain like this: by all kinds of solvents (water and/or organic solvent) decoction and/or supersound extraction and/or diafiltration extraction grape grape section plant, extract one or many, filter, steaming desolventize extractum, in extractum, add hot water, the cooling, leave standstill, detect the active ingredient of precipitation and supernatant, the precipitation part has activity, gets precipitation.
Extract the used preferred alcohols of solvent, esters, ketone, ethers and strong polar organic solvent and/or water, more preferably low-level chain triacontanol, low-grade fatty acid ester, ketone and ether and/or water with 3-12 carbon atom, methanol most preferably, ethanol, propanol, isopropyl alcohol, n-butyl alcohol, isobutanol, sec-butyl alcohol, the tert-butyl alcohol, ethyl acetate, methyl acetate, Ethyl formate, acetone, methyl ethyl ketone, ether, methyl ethyl ether, methyl tertiary butyl ether(MTBE), dichloromethane, chloroform, carbon tetrachloride, dimethyl sulfoxine, N, dinethylformamide and/or water or the like.
The present invention can use all vitaceaes, preferably uses Ampelopsis, more preferably ampelopsis cantoniensis, the beautiful Fructus Vitis viniferae of a leaf, Ampelopsis grossedentata, Cayratia japonica (Thunb.) Gagnep., Radix Ampelopsis, Northeastern Caulis seu folium ampelopsis brevipedunculatae and Vitis Amurensis etc.
Principle of the present invention is to follow the trail of the drug activity position of Caulis seu folium ampelopsis brevipedunculatae (Caulis Ampelopsis Brevipedunculae) by setting up the pharmacological screening model, finds its active medicinal matter.And further find the medicinal usage of flavonid composition of the present invention.The animal model test of the influence of the test of the influence of the mouse experiment liver damage that carbon tetrachloride is caused and mouse experiment liver damage that D-Gal is caused shows that flavonid composition of the present invention has tangible hepatoprotective effect; Extracorporeal bacteria inhibitor test and and antivirus test show that flavonid composition of the present invention has antibacterial and anti-inflammation functions; The test of serum agglutinin shows that extract of the present invention has the effect of enhance immunity systemic immunity power.
Flavonid composition of the present invention can be used for pharmaceutical field, field of health care products and field of food.
Flavonid composition of the present invention and pharmaceutically acceptable carrier or mixed with excipients can be mixed with pharmaceutical composition, and flavonid composition of the present invention can also be as the effective ingredient of health product, and flavonid composition of the present invention can also be mixed with beverage etc.
Pharmaceutical composition of the present invention can be mixed with pharmaceutical composition by conventional preparation technique of drug world and carrier.Flavonid composition of the present invention can be prepared into tablet, granule, and capsule, medicine for external use can also join in the bitter edible plant or the beverage, makes health tea or beverage.
Describe the present invention in detail by the following examples.But should be appreciated that these embodiment just illustrate the present invention, rather than in office where face limits the scope of the invention.Embodiment 1: the method for preparing flavonid composition from the Radix Ampelopsis plant
Under the room temperature,, take percolation to extract with the Radix Ampelopsis root 1500 gram flush away dust of collecting, the total consumption of ethyl acetate is 10000ml, collects solution, and steaming desolventizes, add 1800 milliliters of 90 ℃ of hot water in the extractum, be cooled to 60 ℃, leave standstill, filter, with the filtrate cool to room temperature, leave standstill then, make precipitation, filter, obtain light-yellow precipitate, oven dry obtains total flavones 15.01g.Productive rate: 10.00%.Thin-layer chromatographic analysis polyamide thin layer chromatography, specification 8 * 8cm, developing solvent: methanol, developer: 4% ferric chloride-alcoholic solution, R
The f gallic acid=0.73, R
The f arbutin=0.55, R
The f ampelopsin=0.51, R
The f ampelopsin=0.20, R
F5=0.42.Embodiment 2: the method for preparing flavonid composition from porcelain ampelopsis
Under the room temperature, the Ampelopsis grossedentata 1200 gram flush away dust with collecting add 6000 milliliters of ethanol, decoct 1 hour, filter, residue adds 3000 milliliters of ethanol again, decocts 1 hour again, refilters, filtrate merges, and is concentrated into 2 milliliters, adds 1200 milliliters of 80 ℃ of hot water, is cooled to 60 ℃, leave standstill, filter, then with the filtrate cool to room temperature, leave standstill, make precipitation, filter, obtain light-yellow precipitate, oven dry obtains flavonid composition.Productive rate: 10.57%.Thin-layer chromatographic analysis polyamide thin layer chromatography, specification 8 * 8cm, developing solvent: methanol, developer: 4% ferric chloride-alcoholic solution, R
The f gallic acid=0.72, R
The f arbutin=0.54, R
The f ampelopsin=0.50, R
The f ampelopsin=0.21, R
F5=0.41.Embodiment 3: the method for preparing flavonid composition from the Northeastern Caulis seu folium ampelopsis brevipedunculatae plant
Under the room temperature, the Northeastern Caulis seu folium ampelopsis brevipedunculatae 800 gram flush away dust with collecting add 3000 ml waters, supersound extraction 0.5 hour, filter, residue adds 1000 milliliters of propanol again, and supersound extraction is 0.5 hour again, refilters, filtrate merges, and is concentrated into 2 milliliters, adds 500 milliliters of 100 ℃ of hot water, is cooled to 60 ℃, leave standstill, filter, then with the filtrate cool to room temperature, leave standstill, make precipitation, filter, obtain light-yellow precipitate, oven dry obtains flavonid composition.Productive rate: 8.34%.Thin-layer chromatographic analysis polyamide thin layer chromatography, specification 8 * 8cm, developing solvent: methanol, developer: 4% ferric chloride-alcoholic solution, R
The f gallic acid=0.74, R
The f arbutin=0.56, R
The f ampelopsin=0.51, R
The f ampelopsin=0.20, R
F5=0.42.Embodiment 4: the influence of the mouse test liver damage that flavonid composition of the present invention causes carbon tetrachloride:
Animal is divided into six groups at random: three groups of normal control groups, positive controls, model control group, flavonid composition group of the present invention: 100mg/kg, 200mg/kg, 400mg/kg.The normal control group is that animal is not given any medicine, only gives solvent; Positive controls is bifendate 200mg/kg, qdx6, and po, bifendate is treating hepatitis medicine commonly used, with bifendate treatment animal pattern, observe the curative effect, in contrast; Model control group is the check drug effect, and animal must be made hepatitis model earlier, makes animal suffer from hepatitis; Flavonid composition group of the present invention is on above-mentioned model basis, gives flavonid composition of the present invention again, and with observe the curative effect, three groups all is Bidx6 po.Each treated animal grouping administration, every group of 10 mices, twice on the one, take volume 0.5ml/20g mice, took continuously six days, 0.2ml/ mice of 1 hour lumbar injection 1% carbon tetrachloride oil solution after the last administration, on an empty stomach after 16 hours by the eye socket venous blood collection, separation of serum is measured the SGPT (ALT) of serum, SGOT (AST) content, and serum total bilirubin (T-BIL caffeine sodium benzoate colorimetry) content, and and positive controls, the normal control group, model control group compares, and model control group is taken the equivalent coordinative solvent, and positive controls adopts bifendate 200mg/kg, pox6, once a day.The results are shown in Table 1.Table 1. dihydromyricetin causes the variation of the serum SGOT of mouse liver injury to carbon tetrachloride
* P＜0.05 * * P＜0.01 and model group are relatively from the effect of flavonid composition with excellent treatment hepatitis as can be seen of the data of table 1.And reduction T-BIL content; demonstration is with the hepatoprotective effect embodiment 5 of the tangible reducing enzyme and treating jaundice of flavonid composition: flavonid composition of the present invention causes mouse liver injury to D-galactosamine protective effect is divided into six groups at random with animal; positive controls, model control group, normal control group, flavonid composition group of the present invention; be divided into three groups: 100mg/kg; 200mg/kg; 400mg/kg, the meaning of each group is with above-mentioned embodiment 4.Normal control group, model control group are taken corresponding solvent, positive controls lumbar injection 200mg/kg, pox6, qd, 1 hour D-galactosamine 100mg/kg after the last administration, get blood by eye socket after 16 hours, separation of serum is measured serum SGPT, the variation of serum SGOT, the results are shown in Table 2 tables 2 flavonid composition of the present invention D-galactosamine is caused the serum SGPT of mouse liver injury, the variation of SGOT
* P＜0.05, * * P＜0.01 relatively has fabulous hepatoprotective effect from the data of table 2 flavonid composition of the present invention as can be seen with model group.Embodiment 6: flavonid composition of the present invention is tested at external antibacterial, antiviral:
| Group | Dosage mg/kg | Serum SGPT (U) X ± SD | Serum SGOT (U) X ± SD | ????T-BIL |
| Coordinative solvent | ||||
| Model control group | Coordinative solvent | 109.2_9.8 | ??83.7±4.6 | ??5.78±2.91 |
| Dihydromyricetin | ??50?Bidx6po | 108.3_10.12 | ??79.4±10.3 | |
| Dihydromyricetin | ??100?Bidx6po | 85.3_4.34 | ??71.0±10.4 | ??4.24±2.11 |
| Dihydromyricetin | ??200?Bidx6po | 68.3_4.89* | ??68.4±9.2** | ??3.42±1.32 |
| Bifendate | ??200?qdx6po | 63.6_4.10** | ??61.2±4.2** | ??3.12±1.24 |
| Group | Dosage mg/kg | Serum SGPT (U) X Xu D | Serum SGOT (U) X Xu D |
| The normal control group | Coordinative solvent | ＜40 | 33.7_4.7 |
| Model control group | Coordinative solvent | 90.7_17.3 | 58.3_15.5 |
| Flavonid composition of the present invention | 100?Bidx6po | ?64.7_20.9 | 56.2_17.3 |
| Flavonid composition of the present invention | 200?Bidx6po | ?62.2_12.8 | 48.2_11.0 |
| Flavonid composition of the present invention | 400?Bidx6po | ?46.0_7.8** | 38.5_10.8* |
| Bifendate | 200?qdx6po | ?23.6_3.9** | 33.8_15.2* |
Separation of influenza virus and mirror (dripping) are fixed
Embryo Gallus domesticus at present commonly used separates and carries out influenza virus, and route of inoculation is the allantoic cavity of Embryo Gallus domesticus, occurs the characteristics of lesion of back chicken embryo death after 3 days and hemagglutinin occurs, and to this, we adopt the method to carry out evaluation to flavonid composition of the present invention.We adopt the influenza virus of certain density extracting solution and 4 HAUs to mix at 1: 1, allow the two inject Embryo Gallus domesticus after 20 minutes again in the room temperature effect, and injection volume is every embryo 0.2ml.The Embryo Gallus domesticus of 9 to 11 ages in days is adopted in experiment, carry out the allantoic cavity inoculation, cultivate after 48 hours, placed liquid in 4 ℃, aseptic then its urine of getting, get supernatant through 1000rpm after centrifugal 10 minutes, packing is deposited for-20 ℃, the usefulness that is equipped with detection, the detection of urine divides blood clotting and blood to press down two kinds, and the erythrocyte of use comes prosperous cock, and method is a conventional method.
The antiviral experiment: the flavonid composition of the present invention with variable concentrations carries out antiviral experiment hirst's hemagglutination inhibition test in Embryo Gallus domesticus
Remarks: 1, stock solution refers to the flavonid composition 4mg/ml of the present invention of initial concentration
| The serum dilution sample concentration | Stock solution | 10 × | 20 × | 40 × | 80 × | 160 × | 320 × | 640 × | 128 0× |
| Stock solution 1 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | ||
| Stock solution 2 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | ||
| Stock solution 3 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ | |
| Stock solution 4 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ | |
| 10 -5a | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | +++ + | ++ |
| 10 -5b | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | +++ + | ++ |
| 10 -5c | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | +++ + | |
| 10 -5d | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ | |
| 10 -6a | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | +++ + | |
| 10 -6b | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | +++ + | |
| 10 -6c | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ |
| 10 -6d | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ |
2,10
-5With 10
-6Finger carries out the dilution factor of medicine from flavonid composition stock solution of the present invention
3, press during result of determination blood clotting intensity respectively with ++ ++, +++, ++ ,-expression.
Erythrocyte is the invalid main aperture of fine sand grain sample (pipe) end person +++, i.e. 100% coagulation; Erythrocyte evenly is laid on the end, hole (pipe), but the edge is whole to hole (pipe) end concentrator is not slightly +++, i.e. 75% coagulation; (pipe) end, form a ring-type to erythrocyte in the hole, has little coagulation piece person to be all around ++, i.e. 50% coagulation; (pipe) end, form wad to erythrocyte in the hole, but the edge is smooth inadequately, have slightly all around coagulation piece person for+, i.e. 25% coagulation; (pipe) end, form wad to erythrocyte in the hole, and the smooth neat person in edge is one, does not promptly have coagulation.Embodiment 7. external bacteriostasis tests: the external inhibitory effect test of flavonid composition of the present invention:
Adopt dull and stereotyped punch method to measure the antimicrobial effect of extract.After test tube method and dull and stereotyped punch method are attempted, determined this short method simple and easy to do and consuming time of dull and stereotyped punch method.Adopt five kinds of experimental strains: staphylococcus aureus, escherichia coli, streptococcus pneumoniae, hemolytic chain bacterium, micrococcus catarrhalis carry out effect test.
Stock solution refers to the flavonid composition 4mg/ml remarks of the present invention of initial concentration: mm refers to the diameter of inhibition zone
| The experimental group strain name | Extract concentrations and inhibition zone size (mm) | ||
| Stock solution | 1 times of dilution of extracting solution | Multi-resistance (penicillin and streptomycin, nystatin) | |
| Staphylococcus aureus | ??9.5mm | ????8mm | ????17-20mm |
| Escherichia coli | ??8.5mm | ????6mm | ????11mm |
| Streptococcus pneumoniae | ????- | ?????- | ????10mm |
| The hemolytic chain bacterium | ????- | ?????- | ????10-11mm |
| The mucositis fungus ball | ????- | ?????- | ????11mm |
Embodiment 8
Mouse humoral immune (serum agglutinin) is influenced
1, negative control group
2, aspirin group
3, the heavy dose of group of flavonid composition of the present invention (0.15g/kg, greatly-and 1.35g/kg, dosage group 0.45g/kg) observe the coagulation degree, divide five groups (0-4), calculating antibody result carries out statistical procedures, is calculated as follows antibody product (antibody product ∑=S1+2S2+3S3+4S4 ... NSn)
Table 5, flavonid composition of the present invention are to the influence of mice agglutinin
| Number of animals | The antibody product | The P value | |
| The blank group | 10 | 93.4±13.22 | |
| Aspirin | 10 | 115.00??????± 17.31 | ＜0.01 |
| Flavonid composition small dose group of the present invention | 10 | 103±11.31 | |
| Middle dosage group | 10 | 115.92??????± 19.38 | ＜0.01 |
| Heavy dose of group | 10 | 103±7.01 | ＜0.05 |
The result confirms: middle and high dosage group obviously increases anti-sheep red blood cell agglutinin value in the serum, has
Significant difference, flavonid composition higher dosage of the present invention is engulfed system in the body dictyosome
Function has potentiation.
Embodiment 9 flavonid composition analgesic experiments 1, animal target: Kunming white mice 18～22g male and female half and half 2, grouping and solution preparation:
With 10 every group of white mice, be divided into 5 groups: 1. normal saline group; 2. water extraction group (0.26g/ml); 3. alcohol extract (0.21g/ml); 4. total flavones group (0.15g/ml); 5. dihydromyricetin (0.04g/ml).3, administering mode
Weigh to each group white mice, by every 0.1ml/10g administration, continuous three days gastric infusions, and open 60min after the administration in per 3 days, the abdominal cavity only feeds acetic acid (0.5%) solution 0.2ml/, observes in 5～30min animal and sweeps the body number.4, result and statistics medicine name dosage pain relieving rate P value normal saline 0.2ml/ 0 water is put forward group 2.6g/kg 88.1% P＜0.05 alcohol extraction group 2.1g/kg, 93.5% P＜0.05 total flavones group 1.5g/kg, 88.0% P＜0.05 dihydromyricetin 0.4g/kg, 54.1% P＜0.05 group of result proves: flavonid composition has tangible analgesic effect.
Embodiment 10 total flavones groups meeting thing is to the effect for reducing fat of hyperlipidemia mice blood fat
Dosage TC TG HDL-C group mg/kg (mmol/L) (mmol/ (mmol/L
L)) normal control group 3.91 ± 1.41 ± 1.85 ±
0.78 0.37 0.28 model control group 11.24 ± 2.11 ± 1.35 ±
5.79 0.41 0.52 clofibrate 310 5.12 ± 1.76 ± 1.72 ±
1.14 0.11 0.64 total flavones makes up 400 6.11 ± 1.58 ± 1.621 ± thing 1.90 0.2 0.56
Animal is divided into 4 groups at random, normal control group, positive controls, model control group, extracting solution group.Every group of 10 mices, once-a-day, successive administration 10 days, the normal control group is not given any medicine.All only respectively organize mice in fact, form experimental hyperlipidemia to high lipoprotein emulsion 0.5ml/.Overnight fasting after medication in 10 days.Next day is from the mouse orbit extracting vein blood.Press enzyme process and detect serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C) content.The result shows, the model control group serum TC, and the TG value obviously raises, and the HDL-C value descends.Compare with model control group.The dihydromyricetin group can obviously reduce serum TC, and the TG value also makes HDL-C slightly raise.Illustrate that this flavonid composition can suppress the mice blood fat rising that high lipoprotein emulsion causes, has effect for reducing fat.
Embodiment 11 flavonid compositions are to the phenol red expectorant test experimental technique of mice:
Animal oral test every day sample 1 time, continuous oral three days.Being subjected to test product dosage is 100/kg, and the administration group is pressed the 20ml/kg administration, and negative control group is oral with the volume normal saline.Last administration fasting in preceding 1 day, 0.5 hour lumbar injection 25% phenol red solution 500mg/kg after the last administration, press neck again after 0.5 hour and put to death animal separation trachea, insert entry needle, use the 2ml normal saline flushing, flushing liquor adds 1M NaOH 0.1ml colour developing, in 546mm wavelength colorimetric, directly reads phenol red content with 722 type spectrophotometers.
The table below: represent that from result of the test the dihydromyricetin sample increases the phenol red secretory volume of little will respiratory tract after oral 3 days, the prompting sample has phlegm-dispelling functions.
Table 1, flavonid composition are to the influence of the phenol red expectorant test of mice
Dihydromyricetin 20ml/kg 0.68 ± 0.22-dihydromyricetin 100 0.70 ±-
| Sample dose mg/kg | Phenol red amount (increasing percentage rate ug/ml) |
| ??(X±SD)??????％ |
0.17* * P＞0.05, * * P＜0.05, * * * P＜0.01 are with physiology saline group relatively.Embodiment 12: the prescription of the various preparations of flavonid composition of the present invention
Tablet: flavonid composition 25g of the present invention, lactose 53g, sodium carboxymethyl cellulose
1.5g, magnesium stearate 0.5g, 50% ethanol is an amount of.(regular convention formula: total flavones combination of the present invention
Thing 10%-90% weight ratio, lactose 90%-10% weight ratio, sodium carboxymethyl cellulose
1.5g, magnesium stearate 0.5g, 50% ethanol is an amount of)
Electuary one: 1 part of weight ratio of flavonid composition of the present invention, 2.5 parts of weight ratios of sucrose, 1.25 parts of weight ratios of dextrin, an amount of ethanol.Granulate, dry getting final product (regular convention formula: flavonid composition 5-100% weight ratio of the present invention, (sucrose+dextrin) 95-0% weight ratio, sucrose: dextrin=2: 1) electuary two: flavonid composition 115g of the present invention, Icing Sugar 345g, dextrin 145g, an amount of ethanol, granulation, dry getting final product.Capsule: flavonid composition 100g of the present invention, add 2% starch, behind the mixing, encapsulated.(regular convention formula: flavonid composition 10-100% weight ratio of the present invention, starch 90-0% weight ratio.)
Claims (11)
1. flavonid composition, it contains the ampelopsin of 10-70wt%, the arbutin of 0.5-3wt%, the gallic acid of 0.2-3wt%.
2. the preparation method of the flavonid composition of claim 1 is characterised in that by water and/or organic solvent decoction and/or supersound extraction and/or diafiltration extraction vitaceae, extracts one or many, filter, steam desolventize extractum, in extractum, add hot water, cooling is left standstill, and must precipitate.
3. have treatment hepatitis, hepatoprotective, anti-inflammation, blood fat reducing, analgesia is eliminated the phlegm and the flavonid composition that contains claim 1 of enhance immunity systemic immunity power effect and the pharmaceutical composition of pharmaceutical acceptable carrier or excipient.
4. the beverage or the tea that contain the flavonid composition of claim 1.
5. the method for claim 2, wherein said vitaceae is an ampelopsis.
6. the method for claim 5, wherein said ampelopsis is an ampelopsis cantoniensis, a leaf beautiful Fructus Vitis viniferae, Ampelopsis grossedentata, Cayratia japonica (Thunb.) Gagnep., Radix Ampelopsis, Northeastern Caulis seu folium ampelopsis brevipedunculatae and Vitis Amurensis.
7. the method for claim 2, wherein said solvent is an ethanol, ethyl acetate, acetone and/or water.
8. the purposes of the flavonid composition of claim 1 in the medicine of preparation treatment hepatitis.
9. the flavonid composition of claim 1 is in the medicine of preparation hepatoprotective or the purposes in the health product.
10. the flavonid composition of claim 1 is in the purposes of preparation in the antibacterial-anti-inflammatory drug.
11. the flavonid composition of claim 1 is in the medicine of preparation enhance immunity systemic immunity power and the purposes of health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01109641 CN1375289A (en) | 2001-03-15 | 2001-03-15 | Ampelosis general flavone composition with liver protecting function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01109641 CN1375289A (en) | 2001-03-15 | 2001-03-15 | Ampelosis general flavone composition with liver protecting function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1375289A true CN1375289A (en) | 2002-10-23 |
Family
ID=4658051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01109641 Pending CN1375289A (en) | 2001-03-15 | 2001-03-15 | Ampelosis general flavone composition with liver protecting function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1375289A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117922A1 (en) * | 2004-06-04 | 2005-12-15 | Bright Future Pharmaceutical Laboratories Limited | Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food |
| CN100341416C (en) * | 2003-05-30 | 2007-10-10 | 任启生 | Health food containing ampeloptin |
| CN100345538C (en) * | 2003-05-30 | 2007-10-31 | 任启生 | Use of ampelopsin for preparing blood sugar reducing medicine |
| CN105995916A (en) * | 2016-05-06 | 2016-10-12 | 宋新荣 | Making method of ampelopsis sinica bamboo salt |
-
2001
- 2001-03-15 CN CN 01109641 patent/CN1375289A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341416C (en) * | 2003-05-30 | 2007-10-10 | 任启生 | Health food containing ampeloptin |
| CN100345538C (en) * | 2003-05-30 | 2007-10-31 | 任启生 | Use of ampelopsin for preparing blood sugar reducing medicine |
| WO2005117922A1 (en) * | 2004-06-04 | 2005-12-15 | Bright Future Pharmaceutical Laboratories Limited | Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food |
| CN105995916A (en) * | 2016-05-06 | 2016-10-12 | 宋新荣 | Making method of ampelopsis sinica bamboo salt |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1116293C (en) | Preparation and application of dihydromyricetrin | |
| JP2009542634A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising extract | |
| CN101032547A (en) | Anti-inflammatory and antivirotic medicine composition | |
| CN1131029C (en) | Composite medicine containing dihydromyricetrin | |
| CN101856415B (en) | Chinese herbal medicament oral liquid for treating chicken respiratory infectious disease | |
| CN1375289A (en) | Ampelosis general flavone composition with liver protecting function | |
| CN101588810B (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| KR101119410B1 (en) | Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases | |
| CN102188483B (en) | Extract for treating pharyngolaryngitis and preparation method thereof | |
| CN1504478A (en) | Burnet general saponin extract , its preparation method and use | |
| CN107890486A (en) | A kind of Chinese medicine external anti-inflammation formulation and its preparation method and application | |
| CN111588801B (en) | Traditional Chinese medicine dispersible granule for preventing livestock and poultry epidemic diseases and preparation method thereof | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN1256942C (en) | Application of dihydromyricetrin | |
| CN1267095C (en) | Application use of dihydromyricetrin | |
| CN1943632A (en) | A kind of medicine for treating infant cold and its preparing method | |
| CN102793869A (en) | Traditional Chinese medicine composition for controlling porcine viral diseases and preparation method thereof | |
| CN116637134B (en) | Radix astragali extract of radix Paederiae and its application in preparing medicine for treating chronic pharyngitis | |
| CN118286310B (en) | Application of nux Prinsepiae or extract and composition thereof in treating and/or preventing liver injury | |
| CN107233486A (en) | It is a kind of to treat old salt lemon composition of pharyngitis and preparation method thereof | |
| KR101093731B1 (en) | Liriope platyphylla extracts compositions for treating or preventing inflammatory diseases | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
| CN1939440A (en) | Animal medicament with anthemorrhagic toxin-removing and dysentery-eliminating functions and its preparation | |
| CN105287865A (en) | Medicinal composition for treating malignant tumor | |
| Goel et al. | A Clinical Approach of the Aerial Parts of Tinospora Cordifolia as an Anti-Inflammatory and Other Medicinal Properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |